Melanoma's sugar addiction offers hope for new treatment

April 4, 2014 by Fron Jackson-Webb, The Conversation
Unfortunately, blocking the the melanoma’s glucose supply is not as simple as eating less sugar. Credit: Shutterstock

Melanoma cells are dependent on glucose to grow and spread, Melbourne researchers have found, paving the way for therapies that can halt cancer growth by blocking its fuel source.

Melanoma is the most deadly cancer in Australia, claiming 1,500 lives each year. Without the is around eight months from diagnosis.

Around 40% of melanomas are driven by mutations in the BRAF gene and rely on glucose to drive their aggressive growth.

The study – led by PhD candidate Tiffany Parmenter and co-authored by professors Rod Hicks and Grant McAurthur at the Peter Peter McCallum Cancer Centre – was published today in the journal Cancer Discovery.

The researchers saw a number of patterns in clinical practice and set out to understand the scientific mechanisms that underpinned these changes in patients.

They noticed that tumours driven by BRAF genes had particularly high use of glucose, which was turned off very rapidly after drug therapy – this indicated the medication was working.

"While we know these drugs are incredibly effective in patients who have this particular mutation, it will only stop them growing for a period of time – sometimes years, but unfortunately sometimes it only keeps it under control for weeks," said co-author Professor Rodney Hicks.

The researchers also noticed that before the tumours started to grow again, the melanoma's glucose supply was turned back on and became resistant to the effects of the drug.

The team used a series of different experiments over three years – including genetic analysis, cell culture analysis and tests incubating cells with drugs – to piece together what was occurring.

"We found that the cells were 'addicted' to glucose in their need to grow," Prof Hicks said. Some were so addicted, they would kill themselves as soon as the supply was threatened, while others were able to survive, he said.

The next step is to develop therapies that kill the remaining by "cutting off the fuel supply" or blocking the raft of genes that regulate the uptake and use of glucose.

But unfortunately, blocking the the melanoma's glucose supply was not as simple as eating less sugar, Prof Hicks said.

"Your brain and heart and all your other tissues need sugar so that's not a viable proposition. What we want to do is target a very specific use of glucose in cancer cells."

Professor Rodney Sinclair, Head of the Epworth Dermatology Research Centre, said these cancers were notoriously difficult to treat.

"Melanoma has a tendency to drop seeds into the blood stream and lymphatics that can lay dormant for years before reactivating," he said.

"The seeds are hard to detect and hard to eradicate. Once reactivated they are adaptable and resist chemotherapy that is effective for other types of cancer."

Although modern drugs were able to shrink tumours, he said, they usually did not disappear completely.

"The remaining residual tumour over time finds a way to resist the chemotherapy and then rebounds back. So, rather than a cure, these treatments prolong life by anywhere up to a year or two and then the patient ultimately succumbs to the melanoma."

Cancer biologist Darren Saunders, laboratory head at the Garvan Institute, said the study was important step forward in the development of new combination therapies.

"This study has identified a potential new avenue, and proof of concept, for using BRAF inhibitors in combination with drugs targeting glycolysis," he said.

"Glycolysis is a particular arm of cellular metabolism that converts sugar () into energy and building blocks for new cells.

"There is a rapidly emerging understanding of how cancer cells reprogram their metabolism to use fuels like sugar, fats and amino acids differently to normal cells.

"This reprogramming is a highly attractive target for new therapies and the subject of intense research interest."

Explore further: Blocking glutamine pumps suppresses melanoma cell growth

Related Stories

Blocking glutamine pumps suppresses melanoma cell growth

February 19, 2014
The latest research from Sydney's Centenary Institute and the University of Sydney suggests we could.

Diabetes drug points the way to overcoming drug resistance in melanoma

June 11, 2013
Advanced metastatic melanoma is a disease that has proven difficult to eradicate. Despite the success of melanoma-targeting drugs, tumors inevitably become drug resistant and return, more aggressive than before. In the current ...

Cell metabolism discovery could lead to treatments for cancer, common cold

April 2, 2014
(Medical Xpress)—Scientists at UCLA's Jonsson Comprehensive Cancer Center have published the first study explaining in detail how viruses reprogram the metabolism of the cells they invade to promote continued viral growth ...

New study could enhance treatments for drug-resistant melanoma

November 21, 2013
Melanoma is the deadliest form of skin cancer, killing more than 8,000 in the U.S. each year. Approximately 40 percent of advanced melanoma tumors are driven to grow by the presence of mutations in a gene known as the BRAF ...

BRAF inhibitor treatment causes melanoma cells to shift how they produce energy

March 8, 2013
A multi-institutional study has revealed that BRAF-positive metastatic malignant melanomas develop resistance to treatment with drugs targeting the BRAF/MEK growth pathway through a major change in metabolism. The findings, ...

Blocking autophagy with malaria drug may help overcome resistance to melanoma BRAF drugs

February 24, 2014
Half of melanoma patients with the BRAF mutation have a positive response to treatment with BRAF inhibitors, but nearly all of those patients develop resistance to the drugs and experience disease progression.

Recommended for you

No dye: Cancer patients' gray hair darkened on immune drugs

July 21, 2017
Cancer patients' gray hair unexpectedly turned youthfully dark while taking novel drugs, and it has doctors scratching their heads.

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.